文献速递胸部肿瘤放疗姑息放疗与转移瘤

质子束治疗1-3个肺寡转移瘤的多机构回顾性疗效分析

Multi-Institutional Retrospective Analysis of the Outcomes of Proton Beam Therapy for Patients With 1 to 3 Pulmonary Oligometastases From Various Primary Cancers.
PubMed 文献 · Adv Radiat Oncol · 2021-03-26

日本6家机构回顾性分析118例141个肺寡转移瘤患者接受质子束治疗(PBT)的疗效与毒性。中位随访25.5个月,3年局部无进展率78.4%、总生存率59.6%,≥3级晚期毒性未发生;结直肠癌原发是局部无进展的独立不良预后因素,PS和总肿瘤体积与总生存相关。

要点

  • PBT对1-3个肺寡转移瘤局部控制良好,3年局部无进展率78.4%。
  • 3年总生存率59.6%,≥3级晚期毒性未发生,安全性可接受。
  • 结直肠癌原发是局部无进展的独立不良预后因素(HR 3.31-4.76)。

核心结论

  • PBT对多种原发癌的肺寡转移(1-3个)提供有前景的疗效且毒性可接受。

研究设计与样本

  • 多机构回顾性调查纳入日本6家机构118例患者共141个肺转移瘤,分析局部无进展率、远处无进展率、无进展生存率、病因特异性生存率和总生存率。
  • 采用常见不良事件评价标准(CTCAE)4.0版评估≥2级治疗相关不良反应,并用Cox比例风险回归进行单变量和多变量分析。

主要发现

  • 中位随访25.5个月,原发部位主要为结直肠癌(42.4%)、肺癌(11.9%)、头颈癌(8.5%)和肾癌(8.5%)。
  • 第1、2、3年局部无进展率分别为92.2%、86.3%、78.4%;远处无进展率分别为59.1%、44.1%、34.0%。
  • 第1、2、3年无进展生存率分别为49.6%、31.7%、24.2%;病因特异性生存率分别为83.4%、72.5%、64.8%;总生存率分别为79.0%、67.8%、59.6%。
  • 多变量分析中,结直肠癌原发是局部无进展的唯一独立显著预后因素(3组参数集HR 3.31-4.76);总生存的显著预后因素为体力状况(HR 2.78,95%CI 1.01-7.67)和总肿瘤体积(HR 1.01,95%CI 1.00-1.02)。

关键数值与推荐

  • 局部无进展率第1、2、3年分别为92.2%、86.3%、78.4%。
  • 总生存率第1、2、3年分别为79.0%、67.8%、59.6%。
  • 结直肠癌原发局部无进展多变量分析HR 3.31-4.76(3组参数集)。
  • 总生存多变量分析:体力状况HR 2.78(95%CI 1.01-7.67),总肿瘤体积HR 1.01(95%CI 1.00-1.02)。

临床怎么用

  • 对于1-3个肺寡转移患者,PBT是可考虑的安全有效的局部治疗选择。
  • 结直肠癌肺寡转移患者接受PBT时局部进展风险较高,需加强随访和局部控制策略。
  • 体力状况较差或总肿瘤体积较大的患者总生存预后较差,治疗决策时应综合评估。

局限性

  • 回顾性多机构研究设计可能存在选择偏倚和信息偏倚。
  • 样本量有限(118例),中位随访25.5个月,长期疗效和晚期毒性需更长时间验证。
  • 原发癌种类多样且结直肠癌占比较高,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Our purpose was to evaluate the efficacy of proton beam therapy (PBT) in patients with 1 to 3 pulmonary oligometastases from various primary cancers in Japan. METHODS AND MATERIALS: This multi-institutional retrospective survey included 118 patients with 141 metastatic lung tumors from miscellaneous primary cancers, across 6 Japanese institutions, and involved the analyses of local progression-free rate (LPF), distant progression-free rate, progression-free survival rate, cause-specific survival rate, and overall survival rate (OS). Treatment-induced adverse effects of grade ≥2 were evaluated according to the Common Terminology Criteria for Adverse Events (version 4.0). Cox proportional hazards regression models were used in univariable analysis and multivariable analysis (MVA) for the identification of the prognostic factors of LPF and OS. RESULTS: The median follow-up duration from the time of PBT was 25.5 months. The major primary disease sites included colorectal cancer (42.4%), lung cancer (11.9%), head and neck cancer (8.5%), and kidney cancer (8.5%). For years 1, 2, and 3, LPFs were 92.2%, 86.3%, and 78.4%; distant progression-free rates were 59.1%, 44.1%, and 34.0%; progression-free survival rates were 49.6%, 31.7%, and 24.2%; cause-specific survival rates were 83.4%, 72.5%, and 64.8%; and OS rates were 79.0%, 67.8%, and 59.6%, respectively. Eight patients developed acute adverse effects (grade ≥2). Ten patients developed radiation pneumonitis (grade 2) as a late adverse effect. None of the patients developed severe late toxicity (grade ≥3). Colorectal cancer as the primary disease was the only prognostic factor associated with LPF that remained independently significant in the MVAs performed using 3 sets of parameters (hazard ratio [HR], 3.31-4.76 in 3 MVA sets). In the MVA, the significant prognostic factors for OS were performance status (HR, 2.78; 95% confidence interval, 1.01-7.67) and total tumor volume (HR, 1.01; 95% confidence interval, 1.00-1.02). CONCLUSIONS: PBT provides promising outcomes for pulmonary oligometastasis with acceptable toxicities.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Aibe N, Ogino H, Teramukai S, et al. Multi-Institutional Retrospective Analysis of the Outcomes of Proton Beam Therapy for Patients With 1 to 3 Pulmonary Oligometastases From Various Primary Cancers. Adv Radiat Oncol. 2021. PMID: 34159280. doi:10.1016/j.adro.2021.100690

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。